Alberta Health Services / U Calgary CPT 2026 — Unauthorized injectable peptides clinical pearl

Summary

This is a Clinical Pharmacology & Toxicology “Pearl of the Week” educational bulletin from the Alberta Health Services Clinical Pharmacology service (University of Calgary Cumming School of Medicine, reviewed 2026-04-20). It summarizes four poison-centre case reports of harm from unauthorized injectable peptides (a 66-fold GHK-Cu overdose, an acute CJC-1295 reaction, a peptide-polypharmacy inflammatory response, and an adolescent acute kidney injury / hypoglycaemia case) and reviews the category-level safety problem. The Heavy Metal Index relevance is contained in two general claims drawn from prior literature: that “some [unauthorized injectable peptides] contain toxic contaminants (e.g., arsenic, lead) or undeclared drugs,” and that “falsified peptides have been found to contain arsenic (up to 10× ICH limits), lead, endotoxins, and incorrect or absent active ingredients.” Both claims are tertiary — they cite Janvier et al. 2018 and Vanhee et al. 2015 rather than reporting original measurements — but the bulletin establishes that heavy-metal contamination of unauthorized injectable peptides is now part of formal clinician-facing toxicology guidance from a Canadian poison-control programme. It also documents Health Canada enforcement actions against named vendors of unauthorized injectable peptides (a regulatory-event context per CLAUDE.md Part 12 Exception 1).

Key numbers

This bulletin does not present original elemental-impurity measurements. Two quantitative HM-relevant claims are quoted from the cited literature:

Clinical case detail (not HM-relevant but recorded for context):

• Case 1: 50-year-old female; 132 mg subcutaneous GHK-Cu (66-fold dosing error); asymptomatic; outpatient follow-up.
• Case 2: adult male; 300 µg subcutaneous CJC-1295; immediate diarrhoea and difficulty swallowing saliva; resolved spontaneously.
• Case 3: adult male; ~50 mg combined Alpha-1, 5-amino-1-methylquinolinium, and tesamorelin (10-fold dosing error); CRP 151 mg/L, WBC 24.6 × 10⁹/L; supportive care, discharged.
• Case 4: 17-year-old male; stacked hCG, anastrozole, IGF-1 LR3 and CJC-1295 over five days; acute kidney injury and metabolic alkalosis on initial presentation; severe hypoglycaemia at re-presentation three days after peptide cessation; toxicologist raised undisclosed exogenous insulin as the likely explanation.

Evidence Fitness

Context only. This source carries no original heavy-metal occurrence data, no analytical-method detail, no sample-size attribution, and no LODs against which an HMT&C limit could be reconstructed. Its load-bearing HM-relevant statements (“arsenic up to 10× ICH limits,” “lead, endotoxins, incorrect or absent active ingredients”) are secondary citations to Janvier 2018 and Vanhee 2015, both of which are themselves indexed in this wiki. For occurrence numbers, follow the citation back to the source. What this bulletin does support is contextual: that Canadian provincial poison-control programmes now treat heavy-metal contamination of unauthorized injectable peptides as part of routine clinician-facing toxicology guidance, and that Health Canada has taken enforcement action against named domestic vendors of these products.

Methods (brief)

Educational clinical bulletin; not an analytical study. Sources of information cited in the references list include three Talanta / JAMA studies on falsified-peptide impurity profiling and labelling (Janvier 2018, Vanhee 2015, Van Wagoner 2017), FDA product labels for approved peptide therapeutics (EGRIFTA SV, Increlex, Zycubo), preclinical and clinical pharmacology references for individual peptides (Teichman 2006 for CJC-1295 pharmacokinetics, Tomas 1997 and Kerr 1993 for IGF-1, Xu 2020 for BPC-157), a published case of fasciotomy-requiring compartment syndrome after peptide cocktail injection (Lamour 2024), and Canadian regulatory and pricing references. No original chemical analysis was performed for this bulletin.

Implications

• Adds Canadian provincial toxicology-service framing (Alberta Health Services PADIS, CPSA Messenger guidance) to the unauthorized-injectable-peptide contamination picture relevant to research-chemicals-peptides-sarms and peptides-injectable-hormones.
• Documents named Health Canada enforcement actions against Prime Research (Sherbrooke, QC) and Canada Peptide, supporting the regulatory-context entry for unauthorized injectable peptides as a category subject to active agency surveillance (Part 12 Exception 1 — public-record regulatory event).
• Provides no new occurrence data; for arsenic/lead values in this category use janvier2018-falsified-peptides-elemental-impurities as the primary occurrence source (speciation-confirmed inorganic arsenic at 1660–12,890 ppb in 6/27 falsified peptide preparations).

Wiki pages this source may touch

• research-chemicals-peptides-sarms — regulatory-context entry for unauthorized injectable peptides as a category with documented Pb / As contamination concerns and active Health Canada enforcement.
• peptides-injectable-hormones — specific clinical case context for CJC-1295, tesamorelin, IGF-1 LR3, GHK-Cu, BPC-157.
• arsenic — context-only restatement of the Janvier 2018 finding (arsenic in falsified injectable peptides above ICH parenteral limits).
• lead — context-only restatement of the Janvier 2018 finding (lead exceedance in falsified injectable peptides).

Verification notes

• Document is dated “Created and reviewed April 20, 2026” (p. 6). The raw filename embeds “2024” in error; this is corrected in the cite-key and year: field.
• No individual authors are listed on the document; institutional authorship is the AHS Clinical Pharmacology service and PADIS (24/7 poison-control service for Alberta and the Northwest Territories on the 1-800-332-1414 line, Saskatchewan on 1-866-454-1212). The University of Calgary attribution is by convention — the CPT Pearl of the Week series is produced by the Cumming School of Medicine’s Clinical Pharmacology programme. The authors: field uses corporate-author strings accordingly.
• DOI: none — this is a clinical bulletin, not a journal article; no_doi_assigned: true. The document carries no canonical Web URL on its face; access_url: uses a Google Scholar fallback per the 2026-05-13 DOI-fallback convention. The PDF was retrieved into the manual-fetch corpus.
• Brand firewall (Part 12): Prime Research (Sherbrooke, QC) and Canada Peptide are named, but only inside the regulatory-event context (Health Canada enforcement / seizures). The Zycubo (FDA-approved copper histidinate) and EGRIFTA SV (FDA-approved tesamorelin) references are pharmacological context for the peptide-class discussion, not contamination attributions, and are kept on that basis. No per-brand contamination values are reported.
• Wiki/HMT&C firewall (Part 2): no synthesis claims, no threshold proposals, no consumer risk advisories carried into the wiki page; the bulletin’s own consumer-facing advisories (“Any dose is an overdose”) are summarised as documentation of the clinical-guidance stance, not echoed as wiki claims.
• Speciation: the bulletin says “arsenic,” not “inorganic arsenic.” Recorded as tAs (total arsenic) on this page. The cited Janvier 2018 source IS speciation-confirmed iAs, and the iAs designation appears on the Janvier source page; this tertiary citation does not carry speciation forward.
• matrices: values (injectable-peptide, falsified-medicine, unauthorized-injectable) are outside the standard food-matrix vocabulary in docs/gpt-collaboration/system-prompt.md. Kept consistent with the matrices vocabulary already used on janvier2018-falsified-peptides-elemental-impurities; flagged for vocabulary-list review when the peptide/injectable-medicine matrices are consolidated.
• Product slug research-chemicals-peptides-sarms exists in wiki/products/ as of 2026-06-09 but is not in the 2026-05-18 taxonomy snapshot (snapshot is stale; this is a known condition). Same for peptides-injectable-hormones.
• Sample sizes (sample_n:) intentionally null because the four cases are clinical reports, not analytical samples; the underlying contamination claims have their own sample sizes on the cited primary sources.

Page history

The five most recent substantive edits to this page. The full version history lives in git; when DOI minting comes online (see schema docs), each entry below will also link to a version-pinned DataCite DOI.